Lunit bets a final ₩250B rights issue clears its Volpara debt

Lunit sells AI for cancer care: Lunit INSIGHT reads mammograms for screening, Lunit SCOPE predicts immunotherapy response, and the Volpara acquisition (now Lunit International) added breast-screening AI sold directly to more than 3,000 US hospitals.

Lunit bets a final ₩250B rights issue — funded by shareholders, not lenders — extinguishes the Volpara put options and lets a profitability-first pivot pay for itself.

Founded in 2013 and traded on KOSDAQ, Lunit grew from research into cancer-screening software used by hospitals and drugmakers. In May 2025 it entered the US market by acquiring Volpara (now Lunit International), financing the deal with ₩171.5 billion of convertible bonds — a bet that growth would outrun the debt.

By early 2026 the CB put options had become a wall: with the share price down, CFO Park Hyeon-seong put the worst-case payout at about ₩197 billion, and institutions refused a smaller third-party placement while the risk stood. After an 18% share-price drop, Lunit announced its 'final capital raise' — a ₩250 billion shareholder rights offering at a 25% discount, paired with a 1:1 bonus issue — and a strategic pivot: revenue growing 40–50%, operating costs cut more than 20%, headcount already down 15%, and positive EBITDA targeted by end-2026, a year earlier than planned.

CEO Brandon Suh called it the first time in Lunit's 13-year history that profitability came before growth. The bet was that existing shareholders, not new lenders, would clear the overhang: in April 2026 the ₩211.5 billion offering closed 104.7% subscribed, with Atinum Investment taking about ₩30 billion, removing the put-option risk and the threat of administrative-stock designation; new shares were scheduled to list on May 15.

Convertible bonds with put options put a deadline on the stock: if the share price stayed low, investors could force repayment of roughly ₩197 billion.

Third-party money would not touch Lunit while the put risk stood, so the only fix was a rights issue that let shareholders, not lenders, clear the balance sheet.

Volpara was a long-term bet on a US direct channel to 3,000+ hospitals; the capital raise was the price of keeping that bet alive.

Profitability targets gave the story an exit: cost cuts of 20% plus 40–50% revenue growth promised EBITDA breakeven within the same year.

Growth financed by put-option debt is a clock, not a runway: Lunit cleared the balance-sheet deadline by asking shareholders to subscribe instead of waiting for lenders to price the risk.

By late April 2026 the plan held: shareholders subscribed 104.7% of Lunit's ₩211.5 billion offering, Atinum invested about ₩30 billion, and management said the funds structurally remove the Volpara CB put risk and the administrative-stock concern. CEO Suh repeated that this was the final capital raise and that Lunit would prove EBITDA profitability by the end of 2026. Remaining risk is execution: dilution angered some holders, the targets depend on Volpara's US channel and SCOPE's pharma deals converting to recurring revenue, and the share price must rebuild trust the overhang destroyed.